Ce qui a changé

Premier essai de phase 2 enregistré : NCT07749716 — Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

Autorisé par la Commission européenne contre la pelade sévère chez l'adulte et l'adolescent dès 12 ans. Toujours en cours d'examen par la FDA aux États-Unis.

Premier essai de phase 3 enregistré : NCT07516561 — Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Premier essai de phase 3 enregistré : NCT07435012 — Androgenic Alopecia TH07 Clinical Trial

Registered on ClinicalTrials.gov as NCT07618195: Study of EPI-001 in Patients With Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata

Premier essai de phase 1/2 enregistré : NCT07327359 — A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT07317544 — Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT06562894 — Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

Premier essai de phase 2 enregistré : NCT07011485 — A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

Premier essai de phase 3 enregistré : NCT06916793 — A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT06826196 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Premier essai de phase 3 enregistré : NCT06972264 — Safety and Efficacy of VDPHL01 in Males With AGA

Premier essai de phase 3 enregistré : NCT06501924 — Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Premier essai de phase 3 enregistré : NCT05824065 — Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Premier essai de phase 2/3 enregistré : NCT06724614 — Efficacy and Safety of VDPHL01 in Males With AGA

Premier essai de phase 3 enregistré : NCT05888922 — Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT06104839 — Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT06527365 — Safety and Efficacy of VDPHL01 in Males and Females With AGA

Premier essai de phase 2 enregistré : NCT06444451 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT06393452 — Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

Premier essai de approved enregistré : NCT06240351 — A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Premier essai de phase 2 enregistré : NCT06340360 — A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Premier essai de phase 3 enregistré : NCT06012240 — A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Premier essai de phase 1/2 enregistré : NCT06060977 — A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

Premier essai de phase 2 enregistré : NCT06018428 — A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Premier essai de phase 2 enregistré : NCT06118866 — A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT05910450 — A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Premier essai de phase 2 enregistré : NCT05865041 — Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

Premier essai de phase 2 enregistré : NCT06692465 — To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

Premier essai de phase 2 enregistré : NCT05778825 — A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

Premier essai de phase 2 enregistré : NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT04880889 — BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Premier essai de phase 2 enregistré : NCT05677438 — A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT05636904 — Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

Premier essai de phase 2 enregistré : NCT05496426 — A Study of KL130008 in Adults With Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT05556265 — A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Premier essai de phase 2 enregistré : NCT04011748 — Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

Premier essai de phase 1 enregistré : NCT05324293 — To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

Premier essai de phase 2 enregistré : NCT05368103 — Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT05470413 — Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT06402630 — A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

Premier essai de phase 3 enregistré : NCT06126965 — Phase III Study of KX-826 With Adult Male Patients With AGA

Premier essai de phase 2 enregistré : NCT05205070 — A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT03532958 — Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Premier essai de phase 1/2 enregistré : NCT04945226 — A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

Premier essai de phase 3 enregistré : NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Premier essai de phase 1 enregistré : NCT06468579 — To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Premier essai de phase 3 enregistré : NCT04825561 — A Study to Evaluate the Efficacy and Safety of AD-208

Premier essai de phase 1 enregistré : NCT04805606 — A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843

Premier essai de phase 1 enregistré : NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

Premier essai de phase 3 enregistré : NCT04518995 — Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Premier essai de phase 2 enregistré : NCT05940506 — Phase II Study Evaluating the Efficacy and Safety of KX-826

Premier essai de phase 2 enregistré : NCT04556734 — Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT04346316 — A Phase II Study in Patients With Alopecia Areata

Premier essai de phase 1 enregistré : NCT04214808 — To Evaluate the Pharmacokinetics and Safety of AD-208

Premier essai de phase 2 enregistré : NCT04034134 — Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT04006457 — Long-Term PF-06651600 for the Treatment of Alopecia Areata

Premier essai de phase 3 enregistré : NCT03899259 — A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Premier essai de phase 2/3 enregistré : NCT03898479 — Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Premier essai de phase 1 enregistré : NCT04984707 — Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Premier essai de phase 2/3 enregistré : NCT03732807 — PF-06651600 for the Treatment of Alopecia Areata

Premier essai de phase 2/3 enregistré : NCT03742518 — A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Premier essai de phase 2/3 enregistré : NCT03570749 — A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT03594227 — ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Premier essai de phase 2 enregistré : NCT03351322 — ENERGI-F701 for Female Hair Loss Treatment

Premier essai de phase 2 enregistré : NCT03467412 — To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

Premier essai de phase 2 enregistré : NCT03354637 — A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Premier essai de phase 2 enregistré : NCT03137381 — Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT02636244 — Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

Premier essai de phase 2 enregistré : NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Premier essai de phase 2 enregistré : NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Premier essai de phase 2 enregistré : NCT02919735 — Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

Premier essai de phase 3 enregistré : NCT03004469 — Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT02781311 — A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Premier essai de phase 1/2 enregistré : NCT02793557 — Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

Premier essai de phase 2 enregistré : NCT02561585 — LEO 124249 Ointment in the Treatment of Alopecia Areata

Premier essai de phase 2 enregistré : NCT02553330 — A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Premier essai de phase 2 enregistré : NCT02275351 — A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Premier essai de phase 2 enregistré : NCT02279823 — A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT01673789 — Stem Cell Educator Therapy in Alopecia Areata

Premier essai de phase 1/2 enregistré : NCT01501617 — Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT01325337 — Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Premier essai de phase 1/2 enregistré : NCT01286649 — Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia

Premier essai de phase 1 enregistré : NCT01189279 — Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Premier essai de phase 2 enregistré : NCT01451021 — A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

Premier essai de phase 2 enregistré : NCT00418730 — Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Premier essai de phase 3 enregistré : NCT00441116 — A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia